These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 16173263

  • 1. Successful treatment of resistant Behçet's disease with etanercept.
    Atzeni F, Sarzi-Puttini P, Capsoni F, Mecchia M, Marrazza MG, Carrabba M.
    Clin Exp Rheumatol; 2005; 23(5):729. PubMed ID: 16173263
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of recurrent oral aphthous ulcers with etanercept.
    Scheinberg MA.
    Clin Exp Rheumatol; 2002; 20(5):733-4. PubMed ID: 12412213
    [No Abstract] [Full Text] [Related]

  • 7. Current and future use of anti-TNF agents in the treatment of autoimmune, inflammatory disorders.
    Calamia KT.
    Adv Exp Med Biol; 2003; 528():545-9. PubMed ID: 12918761
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. New approaches in the treatment of Adamantiades-Behçet's disease.
    Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C.
    Curr Opin Rheumatol; 2006 Jan; 18(1):3-9. PubMed ID: 16344613
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.
    Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, Ohno S, Pipitone N, Schirmer M, Stanford M, Wechsler B, Zouboulis C, Kaklamanis P, Yazici H.
    Rheumatology (Oxford); 2007 May; 46(5):736-41. PubMed ID: 17403712
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Etanercept in the treatment of intestinal Behcet's disease.
    Ma D, Zhang CJ, Wang RP, Wang L, Yang H.
    Cell Biochem Biophys; 2014 Jul; 69(3):735-9. PubMed ID: 24622940
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. An unusual case of Behçet's syndrome: triggered by typhoid vaccination?
    Molloy ES, Powell FC, Doran MF, Ryan JG, Mulligan NJ, McCarthy CJ, Keogan MT, McCarthy GM.
    Clin Exp Rheumatol; 2004 Jul; 22(4 Suppl 34):S71-4. PubMed ID: 15515791
    [Abstract] [Full Text] [Related]

  • 16. [10th International Conference on Behçet Syndrome. Berlin, June 27-29, 2002].
    Weschler B.
    Rev Med Interne; 2002 Oct; 23(10):808-9. PubMed ID: 12428481
    [No Abstract] [Full Text] [Related]

  • 17. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
    Benitah NR, Sobrin L, Papaliodis GN.
    Semin Ophthalmol; 2011 Oct; 26(4-5):295-303. PubMed ID: 21958178
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model.
    Choi B, Hwang Y, Kwon HJ, Lee ES, Park KS, Bang D, Lee S, Sohn S.
    J Dermatol Sci; 2008 Nov; 52(2):87-97. PubMed ID: 18585901
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.